Washington: A new intravenous antibody medication, vedolizumab has shown positive results for treating both Crohn`s disease and ulcerative colitis.William Sandborn, MD, principal investigator of the Crohn`s disease study, said the results offer new hope to the more than one million Americans who suffer from inflammatory bowel disease (IBD) and do not respond to treatment. Both studies showed that the use of vedolizumab resulted in remission and discontinued use of prednisone, a common yet difficult to tolerate drug used to treat both diseases."The two trials showed highly encouraging results for patients suffering from moderate-to-severe Crohn`s disease and ulcerative colitis when conventional therapy such as steroids, immune suppressive drugs and anti-tumor necrosis factor (TNF) biologic drugs failed," Sandborn, of the Division of Gastroenterology at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health System, said.
Receptor behind spread of Alzheimer`s, Parkinson`s disease discovered
Insecticide-treated bed nets can end third world`s scourge of filariasis